A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

NCT04049266 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

559

Enrollment

INDUSTRY

Sponsor class

Stopped Primary Endpoint Not Met

Conditions

Wet Macular Degeneration

Interventions

DRUG: KSI-301
DRUG: Aflibercept
OTHER: Sham Procedure

Sponsor

Kodiak Sciences Inc